Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig vs Durvalumab with Chemotherapy in Advanced Biliary Tract Cancer
NCT07221253Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Jul 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of rilvegostomig in biliary tract cancer (BTC), sponsored by AstraZeneca. Started Dec 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07221253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221253.